Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.39
VREX's Cash-to-Debt is ranked lower than
77% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. VREX: 0.39 )
Ranked among companies with meaningful Cash-to-Debt only.
VREX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39  Med: N/A Max: No Debt
Current: 0.39
Equity-to-Asset 0.50
VREX's Equity-to-Asset is ranked lower than
67% of the 216 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. VREX: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
VREX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.85 Max: 0.86
Current: 0.5
0.5
0.86
Interest Coverage 38.33
VREX's Interest Coverage is ranked lower than
54% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. VREX: 38.33 )
Ranked among companies with meaningful Interest Coverage only.
VREX' s Interest Coverage Range Over the Past 10 Years
Min: 38.33  Med: 150.91 Max: 422
Current: 38.33
38.33
422
Altman Z-Score: 4.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 16.28
VREX's Operating Margin % is ranked higher than
84% of the 221 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. VREX: 16.28 )
Ranked among companies with meaningful Operating Margin % only.
VREX' s Operating Margin % Range Over the Past 10 Years
Min: 16.28  Med: 22.68 Max: 25.69
Current: 16.28
16.28
25.69
Net Margin % 10.34
VREX's Net Margin % is ranked higher than
80% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. VREX: 10.34 )
Ranked among companies with meaningful Net Margin % only.
VREX' s Net Margin % Range Over the Past 10 Years
Min: 10.34  Med: 14.36 Max: 16.36
Current: 10.34
10.34
16.36
ROE % 15.18
VREX's ROE % is ranked higher than
79% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. VREX: 15.18 )
Ranked among companies with meaningful ROE % only.
VREX' s ROE % Range Over the Past 10 Years
Min: 12.19  Med: 18.96 Max: 61.29
Current: 15.18
12.19
61.29
ROA % 12.80
VREX's ROA % is ranked higher than
90% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. VREX: 12.80 )
Ranked among companies with meaningful ROA % only.
VREX' s ROA % Range Over the Past 10 Years
Min: 11.36  Med: 15.74 Max: 50.84
Current: 12.8
11.36
50.84
ROC (Joel Greenblatt) % 36.70
VREX's ROC (Joel Greenblatt) % is ranked higher than
76% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.64 vs. VREX: 36.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VREX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 32.03  Med: 44.61 Max: 132.5
Current: 36.7
32.03
132.5
GuruFocus has detected 2 Warning Signs with Varex Imaging Corp $VREX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VREX's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334517    SIC: 3844
Compare:NAS:ABAX, NAS:MEDP, NAS:GHDX, NAS:FMI, NAS:AXDX, NAS:QDEL, NAS:ALOG, NAS:BEAT, NAS:MYGN, NAS:NRCIB » details
Headquarter Location:USA
Varex Imaging Corp is engaged in designing and manufacturing of X-ray tubes, flat panel detectors, imaging software and inspection accelerators.

Ratios

vs
industry
vs
history
PE Ratio 17.35
VREX's PE Ratio is ranked higher than
81% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.35 vs. VREX: 17.35 )
Ranked among companies with meaningful PE Ratio only.
VREX' s PE Ratio Range Over the Past 10 Years
Min: 15.62  Med: 17.22 Max: 18.03
Current: 17.35
15.62
18.03
PE Ratio without NRI 17.35
VREX's PE Ratio without NRI is ranked higher than
82% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.61 vs. VREX: 17.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
VREX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.61  Med: 17.21 Max: 18.03
Current: 17.35
15.61
18.03
PB Ratio 3.70
VREX's PB Ratio is ranked higher than
51% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. VREX: 3.70 )
Ranked among companies with meaningful PB Ratio only.
VREX' s PB Ratio Range Over the Past 10 Years
Min: 3.34  Med: 3.69 Max: 3.84
Current: 3.7
3.34
3.84
PS Ratio 2.65
VREX's PS Ratio is ranked higher than
64% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. VREX: 2.65 )
Ranked among companies with meaningful PS Ratio only.
VREX' s PS Ratio Range Over the Past 10 Years
Min: 2.39  Med: 2.64 Max: 2.75
Current: 2.65
2.39
2.75
Price-to-Free-Cash-Flow 31.12
VREX's Price-to-Free-Cash-Flow is ranked lower than
59% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.66 vs. VREX: 31.12 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VREX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 27.99  Med: 30.85 Max: 32.31
Current: 31.12
27.99
32.31
Price-to-Operating-Cash-Flow 24.44
VREX's Price-to-Operating-Cash-Flow is ranked lower than
64% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.27 vs. VREX: 24.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VREX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.94  Med: 24.19 Max: 25.31
Current: 24.44
21.94
25.31
EV-to-EBIT 13.65
VREX's EV-to-EBIT is ranked higher than
80% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.02 vs. VREX: 13.65 )
Ranked among companies with meaningful EV-to-EBIT only.
VREX' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.5  Med: 13.65 Max: 14.2
Current: 13.65
12.5
14.2
EV-to-EBITDA 11.53
VREX's EV-to-EBITDA is ranked higher than
76% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.53 vs. VREX: 11.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
VREX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.5  Med: 11.5 Max: 11.93
Current: 11.53
10.5
11.93
Current Ratio 2.91
VREX's Current Ratio is ranked higher than
56% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.72 vs. VREX: 2.91 )
Ranked among companies with meaningful Current Ratio only.
VREX' s Current Ratio Range Over the Past 10 Years
Min: 2.91  Med: 4.63 Max: 4.94
Current: 2.91
2.91
4.94
Quick Ratio 1.46
VREX's Quick Ratio is ranked lower than
68% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. VREX: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
VREX' s Quick Ratio Range Over the Past 10 Years
Min: 1.46  Med: 1.97 Max: 2.25
Current: 1.46
1.46
2.25
Days Inventory 152.75
VREX's Days Inventory is ranked lower than
75% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. VREX: 152.75 )
Ranked among companies with meaningful Days Inventory only.
VREX' s Days Inventory Range Over the Past 10 Years
Min: 62.66  Med: 150.37 Max: 182.79
Current: 152.75
62.66
182.79
Days Sales Outstanding 69.30
VREX's Days Sales Outstanding is ranked lower than
59% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.14 vs. VREX: 69.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
VREX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68  Med: 68.56 Max: 71.93
Current: 69.3
68
71.93
Days Payable 43.75
VREX's Days Payable is ranked lower than
65% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.94 vs. VREX: 43.75 )
Ranked among companies with meaningful Days Payable only.
VREX' s Days Payable Range Over the Past 10 Years
Min: 37.52  Med: 41.14 Max: 47.53
Current: 43.75
37.52
47.53

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 17.00
VREX's Price-to-Net-Current-Asset-Value is ranked lower than
70% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.67 vs. VREX: 17.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VREX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 16.8  Med: 16.8 Max: 17.65
Current: 17
16.8
17.65
Price-to-Tangible-Book 5.09
VREX's Price-to-Tangible-Book is ranked higher than
50% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.04 vs. VREX: 5.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VREX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.03  Med: 5.03 Max: 5.28
Current: 5.09
5.03
5.28
Price-to-Median-PS-Value 1.01
VREX's Price-to-Median-PS-Value is ranked higher than
52% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. VREX: 1.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VREX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1  Med: 1 Max: 1.05
Current: 1.01
1
1.05
Price-to-Graham-Number 1.98
VREX's Price-to-Graham-Number is ranked higher than
71% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. VREX: 1.98 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VREX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.96  Med: 1.96 Max: 2.06
Current: 1.98
1.96
2.06
Earnings Yield (Greenblatt) % 7.32
VREX's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. VREX: 7.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VREX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 7.06  Med: 7.3 Max: 8
Current: 7.32
7.06
8

More Statistics

Revenue (TTM) (Mil) $635.70
EPS (TTM) $ 1.96
Short Percentage of Float8.58%
52-Week Range $25.00 - 36.58
Shares Outstanding (Mil)37.56
» More Articles for VREX

Headlines

Articles On GuruFocus.com
Varex Imaging To Highlight Advanced Imaging Components At China International Medical Equipment Fair May 11 2017 
Varex Imaging Announces Financial Results For The Second Quarter Of Fiscal Year 2017 May 04 2017 
Varex Imaging Completes Acquisition Of PerkinElmer's Medical Imaging Business May 01 2017 
Varex Imaging Schedules Second Quarter FY17 Earnings Release And Conference Call Apr 17 2017 
Varex Imaging Names Dr. Chertoff To Board Of Directors Apr 03 2017 

More From Other Websites
Varex Imaging Corp. breached its 50 day moving average in a Bullish Manner : VREX-US : June 20, 2017 Jun 20 2017
ETFs with exposure to Varex Imaging Corp. : June 15, 2017 Jun 15 2017
Varex Imaging Corp. breached its 50 day moving average in a Bearish Manner : VREX-US : June 7, 2017 Jun 07 2017
2017 Tech IPO Examines Potential New Buy Zone May 30 2017
Varex Imaging Corp. – Value Analysis (NASDAQ:VREX) : May 25, 2017 May 25 2017
Varex Imaging Corp. breached its 50 day moving average in a Bearish Manner : VREX-US : May 24, 2017 May 24 2017
Billionaire Einhorn Trims Apple, Adds GM, Exits Yelp in Q1: 13F Filing May 16 2017
Varex Imaging To Highlight Advanced Imaging Components At China International Medical Equipment Fair... May 11 2017
Varex Imaging Announces Financial Results For The Second Quarter Of Fiscal Year 2017 May 04 2017
Varex Imaging Completes Acquisition Of PerkinElmer's Medical Imaging Business May 01 2017
Varex Imaging Schedules Second Quarter FY17 Earnings Release And Conference Call Apr 17 2017
Varex Imaging Names Dr. Chertoff To Board Of Directors Apr 03 2017
Varex Imaging Announces Renewed Pricing Agreement With Toshiba Medical Systems Mar 22 2017
Varex Imaging To Showcase A Range Of Advanced X-Ray Tubes And Digital Image Detectors For High... Jan 31 2017
Varex Imaging Completes Separation From Varian Medical Systems, Lists On The Nasdaq Stock Market Jan 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}